alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › treatment

treatment

8 studies tagged treatment, dated 2002-05-01 to 2025-05-20. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Rapamycin treatment for Alzheimer's disease and related dementias: a pilot phase 1 clinical trial 2025-05-20
  2. Expected wait times for access to a disease-modifying Alzheimer's treatment in England: A modelling study 2023-11-06
  3. Preparedness of the Brazilian health-care system to provide access to a disease-modifying Alzheimer's disease treatment 2022-09-05

Studies

8 studies carry this tag.

Date range

2002 to 2025

Top journals

  • Alzheimer's & dementia : the journal of the Alzheimer's Association 1
  • CNS drugs 1
  • Communications medicine 1
  • Experimental neurology 1
  • Journal of Alzheimer's disease : JAD 1

8 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Rapamycin treatment for Alzheimer's disease and related dementias: a pilot phase 1 clinical trial

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Communications medicine 2025-05-20 Biomarkers

    Rapamycin is not detectable in the CSF before or after treatment, but several Alzheimer's disease and inflammatory biomarkers increase after treatment.

  2. Expected wait times for access to a disease-modifying Alzheimer's treatment in England: A modelling study

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of health services research & policy 2023-11-06 Biomarkers

    The NHS England lacks capacity to provide timely access to a disease-modifying treatment, which is estimated to result in significant wait times and potentially avoidable disease progression.

  3. Preparedness of the Brazilian health-care system to provide access to a disease-modifying Alzheimer's disease treatment

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2022-09-05 Biomarkers

    Brazil has no national dementia strategy or established pathway for evaluation of cognitive concerns, and dementia is typically diagnosed late if at all.

  4. Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. CNS drugs 2013-07-01 Tau biomarkers

    Research in animals and humans has associated Alzheimer's disease (AD) with decreased cerebrospinal fluid levels of insulin in combination with decreased insulin sensitivity (insulin resistance) in the brain.

  5. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of Alzheimer's disease : JAD 2011-01-01 Tau biomarkers

    There is an urgent need to find effective presymptomatic Alzheimer's disease (AD) treatments that reduce the risk of AD symptoms or prevent them completely.

  6. Anti-inflammatory treatment in AD mice protects against neuronal pathology

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Experimental neurology 2009-08-10 Biomarkers

    Prior studies suggest that non-steroidal anti-inflammatory drugs (NSAIDs) may lower the incidence of Alzheimer's disease (AD) and delay onset or slow progression of symptoms in mouse models of AD.

  7. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Neurobiology of aging 2008-02-21 Tau biomarkers

    Intravenous immunoglobulin (IVIg) has been proposed as a potential agent for Alzheimer's disease (AD) immunotherapy because it contains antibodies against beta-amyloid (Abeta).

  8. Chronic nicotine treatment reduces beta-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw)

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of neurochemistry 2002-05-01 Biomarkers

    Alzheimer's disease neuropathology is characterised by beta-amyloid plaques and neurofibrillary tangles.

All topic tags with their study counts